Quick Context — How We Got Here

• What was the trigger moment that made you consider taking a corporate strategic investor right now? Options: New enterprise opportunity opened, Board asked us to explore strategic capital, Lead VC suggested strategic partner, Product-market inflection, Other
• Sum up in one sentence what a successful strategic investment would change for your company.
• Which role on your team will be the day-to-day owner of the commercial relationship with a corporate investor? Options: CEO, Head of Sales/Revenue, Head of Partnerships/BD, Head of Product, COO, Other
• How urgent is accelerating enterprise sales for your current roadmap? Options: Immediate (0–3 months), Near-term (3–6 months), Medium (6–12 months), Longer-term (>12 months)
• If this choice turned out to be the wrong one, what would it cost you—operationally, financially, and emotionally?

Who's Steering the Ship — and Who’s Likely to Push Back?

• Which individual investor or board member could realistically veto or materially slow a strategic investment, and why would they?
• Where does your lead VC currently stand on bringing in strategic/corporate capital? Options: Fully supportive, Open but cautious, Neutral / undecided, Opposed
• Has the board asked for references from the corporate investor’s portfolio? If so, how many and what types of companies did they request? Options: No references requested, Asked for 1–2, Asked for 3 or more, Don't know / not asked yet
• What specific concerns do portfolio references typically raise that matter most to your board?
• Which governance terms would your board consider non-starters (select all that apply)? Options: Exclusivity, Right of First Refusal (ROFR), Forced board seat, Veto over strategic partnerships, Long lock-ups or transfer restrictions, Other
• How do you expect the founder team's view to differ from the board's on taking strategic capital?

Decision Clock — Who Decides and How Fast?

• If we needed a clear yes/no within three weeks, what would realistically make that possible — and what would block it?
• Who holds final sign-off on new investors in practice? Options: Board majority, Lead VC endorsement, CEO with board notification, Special committee, Other
• Which internal processes have historically caused the biggest delays during fundraises? Options: Board scheduling, Legal negotiations, Investor due diligence, Valuation disputes, Other
• What is the shortest timeline your team would accept to close this round? Options: 1–3 weeks, 3–6 weeks, 6–12 weeks, >12 weeks
• What concrete documents, assurances, or commitments would you need from us to convince the board this investor won’t add restrictive commercial constraints?

Is a Corporate Check a Catalyst—or a Cautionary Signal?

• How concerned are you that a corporate investment will be interpreted as an acquisition signal and chill other investors or partners? Options: Very concerned, Somewhat concerned, Neutral, Not concerned
• Share a recent example where a strategic investor either accelerated or harmed another startup's partnerships or fundraising. What happened?
• Which customers or strategic partners would we need to reassure about this investment, and what form would that reassurance need to take?
• How important is preserving perceived independence to your next‑round valuation and partnership conversations? Options: Critical, Important, Nice-to-have, Not important
• What public or board messaging would make you comfortable with a corporate investor on the cap table? Options: Joint press release, Board Q&A memo, One-pager on scope of partnership, No public announcement, Other

What Outcomes Would Make This Worthwhile?

• If a corporate partnership shortened your enterprise sales cycle by 6–12 months, what measurable business changes would that create?
• Which KPIs would you use to evaluate our commercial value (select up to three)? Options: ARR growth, Enterprise pipeline velocity, Deals closed (enterprise), Average contract value, Customer retention / NRR, New logo acquisition
• What is your current average enterprise sales cycle from qualified lead to close? Options: <3 months, 3–6 months, 6–12 months, >12 months
• Quantitatively, how many enterprise logos or how much ARR would you expect introductions to plausibly generate within 6 months?
• Which types of operational support matter most to closing enterprise deals for you? Options: Platform integrations / APIs, Joint go-to-market playbooks, Co-sell introductions, Shared customer pilots, Technical onboarding resources, Marketing co-marketing

Past Partnerships — What Worked (and What Broke)

• Tell us about a past partnership that genuinely moved the needle for you—what made it different?
• Describe a partnership that underdelivered. What were the root causes?
• When parent companies deprioritized partners in the past, which early warning signs appeared? Options: Leadership change, Budget reallocation, Roadmap shift, No dedicated partner owner, Slow response times
• How often do you require shared executive sponsorship to keep a strategic partnership alive? Options: Always, Often, Sometimes, Rarely, Never
• Who on a corporate investor's side would need to remain engaged to avoid orphaning this relationship?

Governance Boundaries — What's Off the Table?

• What single governance request from an investor would make you walk away even if the capital solved your near-term problems?
• Which governance constraints are you most sensitive to right now? Options: Exclusivity, ROFR / FOFS, Forced board seat, Strategic veto rights, Lengthy lock-ups, Other
• Would you accept a non-voting observer or advisory role instead of a board seat from a corporate investor? Options: Yes, Maybe with limits, No
• How flexible is your cap table and governance structure to absorb a strategic investor without adding a board director?
• Are there legal protections or charter provisions your counsel relies on that we should be aware of?

Signals & Deal Fit — How We'll Know This Is Right

• What are the three unambiguous signals that would make you certain a corporate investor is the right strategic partner?
• Which internal milestones should be hit before committing to onboarding (e.g., pilot customer, integration readiness)? Options: Integration / API readiness, Pilot customer contract signed, Executive sponsors assigned, Security/compliance clearance, Other
• Would speaking to 3+ founders who've worked with this corporate investor satisfy your board's reference requirement? Options: Yes, Maybe, No
• Which commitments from us would shorten your decision timeline most (select all that apply)? Options: Standard market terms, Written no-exclusivity pledge, Rapid investment committee decision, Reference calls scheduled, Pilot commitment
• How would you prefer we document and present those commitments for efficient board review? Options: Standard term sheet + highlights, One-page commitment letter, Live Q&A with IC, Reference call summaries, Other

Final Reflections — Risks You Can't Ignore

• If a worst-case scenario unfolds post-investment, which single risk would most damage your company's trajectory?
• How resilient is your team to leadership or strategic changes at a corporate investor? Options: Very resilient, Somewhat resilient, Not resilient, Unsure
• What's your contingency plan if promised introductions or integrations stall for six months?
• How will you explain to existing and future financial investors that this strategic investment won’t constrain exit or future financing options?
• Have your legal advisors already flagged any red-line terms common in strategic term sheets? Options: Exclusivity / ROFR flagged, Governance / board seat flagged, Long lockups / transfer restrictions flagged, No major flags, Not reviewed yet

Putting First Steps on the Table

• Assuming we can meet your non-negotiables, what would be the next step you’d want from us to move toward a term sheet? Options: Introductory IC meeting, Standard term sheet, Reference calls arranged, Pilot / integration commitment, Other
• Who should be in the room for our next conversation (names and roles)?
• What timeline would you set for a decision checkpoint with your board? Options: 1 week, 2 weeks, 3–4 weeks, At next scheduled board meeting, Other
• What would success look like at the end of that meeting — what specific approvals or signals should we aim to get?
• What documents or data should we prepare to help your board feel comfortable and move quickly? Options: Term sheet & impact summary, Reference call list, Pilot / integration plan, Customer references / case studies, Other

Quick Snapshot: Where Are You Right Now?

• Which stage and round are you actively pursuing right now? Options: Series A, Series B, Series C, Other / Pre-Series A
• What is your current ARR or most relevant revenue signal (or closest proxy) and growth rate over the past 12 months?
• Who are your primary customer segments today (pick all that apply)? Options: Enterprise / F1000, Mid-market, SMB, Startups, Platform / ISV partners, Other
• Roughly how long does a typical enterprise deal take from first demo to closed-won today? Options: <3 months, 3–6 months, 6–12 months, >12 months, Not applicable / No enterprise deals yet
• How would you summarize— in one sentence— the biggest commercial challenge you’re trying to solve with an investor partner?

Are You Being Seen as a Prize or a Target?

• How worried are you that taking corporate capital will change how buyers, partners, or future VCs perceive your company? Options: Very worried, Somewhat worried, Neutral, Not worried
• Can you describe any specific signals (press, customer questions, or partner behavior) that have already suggested you might be perceived as an acquisition target?
• Have potential or current customers ever hesitated to partner because they thought a strategic investment implied acquisition risk? Options: Yes — frequently, Occasionally, Rarely, Never
• If investors or partners asked directly whether you plan to sell in the near term, what is your honest response and how does that land with your board?
• What would ease your concern about market perception—an explicit clause, a public message, references from other portfolio founders, or something else? Options: Public messaging plan, Non-acquisition commitments in docs, Founder testimonials from other portfolios, Time-limited partnership terms, Other

Who Really Moves the Needle on Decisions?

• Which single person or group on your cap table ultimately decides whether a strategic investor is acceptable? Options: Founder / CEO, Lead VC, Board chair, Full board vote, Other
• Who on your board is most skeptical about strategic corporate investors, and what are their core objections?
• Has your lead VC ever required changes to governance terms in prior rounds—what specifically did they insist on?
• What timeline does your board expect to approve new investors during this round? Options: <2 weeks, 2–4 weeks, 4–8 weeks, >8 weeks
• If a corporate investor could sign a term sheet in 3 weeks with standard VC terms, how would that change discussions with your board and lead VC? Options: Greatly accelerates approval, Helpful but needs references, Neutral, Still problematic

Where Do Commercial Doors Actually Open?

• Which channel today produces your highest-quality enterprise pipeline—direct sales, partner referrals, product-led, platform integrations, or something else? Options: Direct sales / AE, Partner referrals, Product-led / self-serve, Platform / ISV integrations, Inbound content / marketing, Other
• Of the channels you selected, what specific proof can you show that a corporate partner would materially accelerate pipeline velocity or win rates?
• Have you previously integrated with a large platform or completed a joint sales motion? Tell us the outcome and timeline.
• Which partnership outcomes would matter most in the first 6–12 months (pick top three)? Options: Qualified introductions to named accounts, Co-sell engagements, Technical integration / joint product roadmap, Joint GTM campaigns, Referenceable pilot customers, OEM or reseller agreements
• What internal resources do you currently have to execute on integrations and co-sell (engineers, partner managers, solution architects)? Options: Dedicated partner/alliances lead, Engineering bandwidth for integrations, Customer success team for pilots, No dedicated resources, Other

When Past Partnerships Didn’t Deliver, Why?

• What’s the most vivid example you have of a corporate partnership that promised much but failed—what happened?
• Which of the following factors contributed to that failure? Options: Lack of executive sponsorship, Misaligned incentives, No integration resources, Organizational re-prioritization, Lengthy procurement / legal cycles, Other
• How long did it take for the partner to deliver on their first meaningful commercial intro or pilot, and how did that compare to expectations? Options: <1 month, 1–3 months, 3–6 months, >6 months, Never delivered
• When engagement stalled, who on the partner side did you try to escalate to, and what was the outcome?
• If you had a do-over on that partnership, what one structural change would you make to prevent orphaning?

What Would Real Commercial Acceleration Look Like?

• If a corporate investor could accelerate your enterprise pipeline, what three measurable outcomes would prove value in 6 months? Options: % increase in pipeline value, Number of qualified enterprise leads, Shortened sales cycle length, Closed ARR from partner accounts, Number of co-sell opportunities, Other
• What minimum uplift in win rate or deal velocity would justify accepting strategic capital (be specific)?
• How soon do you need those results to start showing to feel comfortable with the partnership? Options: <3 months, 3–6 months, 6–12 months, 12+ months
• Which KPIs will your board ask for to validate the investor’s commercial contribution? Options: Pipeline value by partner-led deals, Deal conversion rate, Time-to-first-intro, Customer retention / churn, Referenceable wins, Other
• If we proposed an initial 3-month pilot co-sell motion, what would success look like to you and your board?

What Red Lines Keep You Up at Night?

• Which governance or commercial clauses would be immediate deal-breakers for you or your lead VC? Options: Exclusivity, Right of First Refusal (ROFR), Forced board seat, Veto over strategic partnerships, Restrictive IP terms, None of the above
• Have you ever had to renegotiate terms after signing because a corporate partner pushed for more control? What happened?
• If a corporate investor commits publicly to standard VC economics and no exclusivity, how important is signing that into the term sheet vs. having verbal assurances? Options: Must be in term sheet, Prefer term sheet but verbal okay short-term, Verbal assurances acceptable, Unsure
• Rank these negotiation priorities for you and your board: speed of close, governance protections, commercial commitments, valuation. Options: Speed of close, Governance protections, Commercial commitments, Valuation
• What concessions—if any—would you consider making to obtain faster commercial access from a strategic investor?

If We Were to Partner, What Does Onboarding Need to Look Like?

• How mature is your product’s integration surface (APIs, docs, SDKs) to support a meaningful platform partnership? Options: Production-ready APIs and docs, Basic APIs with limited docs, SDKs in progress, No APIs yet
• Which onboarding elements would you need from a corporate investor to be comfortable launching co-sell (pick all that apply)? Options: Dedicated partner manager, Integration engineering support, Joint GTM playbook, Named account introductions, Sales enablement materials, Legal / procurement support
• How many engineering and GTM FTEs could you allocate to a partnership in the first 90 days? Options: None, 1–2, 3–5, 6–10, 10+
• What internal systems or data (customer lists, CRM tags, success metrics) would you be willing to share to enable joint pipeline tracking?
• Who on your team would own the partnership week-to-week and who would be the executive sponsor?

How Will This Survive Corporate Change?

• How concerned are you that a change in leadership at a corporate investor could deprioritize your partnership? Options: Very concerned, Somewhat concerned, A little concerned, Not concerned
• Have you experienced a partnership being deprioritized due to a leadership change—what early warning signs did you see?
• What contractual or operational assurances would make you confident the relationship would survive org shifts? Options: Named sponsor commitments, Escalation SLA, Time-bound commercial milestones, Board-level commitments, Regular executive reviews
• How often would you expect formal check-ins with the corporate sponsor in the first year? Options: Weekly, Bi-weekly, Monthly, Quarterly, Ad-hoc / as needed
• If the parent company deprioritized the program, what contingency actions would you expect them to take to avoid orphaning?

Next Steps: What Would Help You Decide?

• What three pieces of evidence would you need from a corporate investor to move from curious to comfortable (e.g., founder references, documented SLAs, sample term sheet)?
• How fast would your board need the investor to be able to close and wire funds for this round to consider them acceptable? Options: Within 1 week, 2–3 weeks, 3–6 weeks, 6+ weeks
• Would you want an initial time-boxed pilot (co-sell or integration) before committing to full terms? If so, how long? Options: Yes — 1 month, Yes — 3 months, Yes — 6 months, No, not necessary
• Which format do you prefer for validating references: live calls with founders, written case studies, or introductions to previously partnered customers? Options: Live founder calls, Written case studies, Intro to partner customers, Combination
• Is there any additional context—sensitive board dynamics, past agreements, or timelines—we should know to surface issues early?

Quick Intro — Help Us See You in a Sentence

• Tell us your name, role, and one-sentence company elevator pitch (what problem you solve and for whom)
• Which round are you raising and what is the target raise amount? Options: Pre‑Seed, Seed, Series A, Series B, Series C, Other
• What is your ideal close timeline for this round? Options: Within 2 weeks, 2–4 weeks, 1–2 months, 2–3 months, Longer / flexible
• Who are your existing lead investors today? (select all that apply) Options: Lead financial VC, Syndicate of VCs, Angel(s), Corporate VC, No outside investors yet, Other
• How many board or observer seats will this round change or create? Options: No change, Creates 1 seat, Creates 2+ seats, Not sure yet
• What would you most want a strategic corporate investor to help you accelerate—revenue, product integrations, go‑to‑market credibility, or something else? Options: Revenue / enterprise pipeline, Product integrations, Channel / resell partnerships, Credibility with enterprise buyers, Talent / hiring support, Other

What Keeps Your Board Up at Night?

• If your board met this week and could only focus on one threat to the company’s next 12 months, what would they say it is?
• How vocal is your lead VC about the prospect of taking corporate capital—are they skeptical, neutral, or encouraging? Options: Skeptical / cautious, Neutral / open, Encouraging / supportive, No strong view
• Has there already been a board conversation about the signaling risk of corporate investment (acquisition optics) — what was the outcome and how long ago? Options: No conversation yet, Briefly discussed, Detailed conversation — leaning against, Detailed conversation — leaning in
• Which of these board-level acceptance criteria are non‑negotiable for you or your lead investor? (select all that apply) Options: No exclusivity, No ROFR/ROFO, No forced board seat, Standard VC economics only, Fast decision timeline, References from 3 portfolio CEOs, Other
• How does the thought of a corporate investor changing product roadmap priorities make you feel? Options: Very anxious, Somewhat concerned, Neutral, Optimistic
• Can you share a short example of a prior investor decision that caused board tension—and what it taught you?

Show Me Where the Deals Actually Come From

• If your sales funnel were a map, where are the most frequent sources of large enterprise opportunities today? Options: Inbound (content/website), Financial VC intros, Partner referrals, Outbound by sales team, Pilot customers, Other
• How long is your average enterprise sales cycle today (from first meaningful contact to close)? Options: <3 months, 3–6 months, 6–12 months, >12 months, Varies widely
• What specific bottleneck most commonly stalls your deals (procurement, integration proof, executive buy‑in, legal terms, budget timing)? Options: Procurement, Integration / technical proof, Executive sponsorship, Legal / contracting, Budget cycles, Other
• Share a recent enterprise win — what role did external introductions or partner support play?
• How many enterprise customers (annual recurring revenue >$100k) are in your pipeline now and how many are expected to close in the next 90 days? Options: 0, 1–3, 4–9, 10+, Unsure
• What would shorten your average sales cycle by 30–50%—specific resources, people, or technical changes?

Is This Round About Cash or Strategic Acceleration?

• If you had to pick one single outcome this investment must deliver, would it be runway extension, acceleration of enterprise ARR, strategic partnership, or optionality for exit—why that one? Options: Runway / runway extension, Accelerate enterprise ARR, Strategic partnerships / integrations, Exit optionality / M&A path, Other
• Have you quantified the revenue or pipeline lift you expect from a corporate partner (dollars, deal velocity, conversion rate)? If so, what are the numbers and assumptions?
• Which of the following commercial commitments from a corporate investor would be most valuable to you? Options: Named co‑sell introductions, Technical integration resources, Joint GTM campaigns, Sales training/coaching from their field teams, Channel/resell agreement
• How do you prefer commercial commitments to be structured—timeboxed milestones, measurable KPIs, or softer 'good faith' introductions? Options: Firm, measurable milestones, Timeboxed commitment with check‑ins, Soft introductions without KPIs, Hybrid
• If a strategic investor promises a 6–12 month pipeline acceleration but then the parent’s priorities change, how would that outcome affect your fundraising and retention plans?

If the Corporate Partner Actually Delivered, What Would You See?

• Imagine six months after onboarding: what three concrete signals would prove the partnership materially accelerated your enterprise traction?
• Which metrics would you want us to report on monthly during the first 6 months? (select up to three) Options: Number of co‑sell introductions, Pipeline value influenced, Deals closed attributable to partner, Average sales cycle length, Customer churn / NPS, Integration milestones met
• Who in your team would own co‑selling activities and post‑close customer success, and do they have experience working with large strategic partners? Options: CEO, Head of Sales, Head of Partnerships/BDR, VP Customer Success, No dedicated owner yet
• Describe the ideal handoff from our corporate teams to yours when an introduction is made—what does success look like in the first 30, 60, 90 days?

Who Gets a Vote and Who’s Scared to Speak?

• Who on your cap table must explicitly approve a corporate strategic investor for the round to close, and how quickly can they act? Options: Lead VC only, Full board approval required, Investor committee needed, Founder decision, Unsure
• Have you already run our terms or similar corporate terms past your lead VC or legal counsel—what feedback did they give and how long ago? Options: Not yet, Discussed informally, Reviewed and flagged concerns, Reviewed and supportive
• What specific governance red lines would immediately stop the deal for you or your lead investor (select all that apply)? Options: Any exclusivity, ROFR/ROFO, Forced board seat, Non‑standard economic terms, Control provisions, Other
• How important is the ability to speak with at least three current portfolio CEOs who received similar promises from a corporate investor before you commit? Options: Critical, Helpful, Optional, Not needed
• Tell us about a time you accepted help that later felt like strings attached—what happened and how did you resolve it?

Can Your Team Take an Integration and Run?

• If we promised a technical integration with a parent product within 90 days, is your engineering org resourced to complete required work on that timeline? Options: Yes, ready now, Yes, with modest effort, No, would need more resources, Unclear / need to investigate
• What internal resources would you commit to a co‑sell program (select all that apply)? Options: Dedicated partnership manager, Sales engineer for joint demos, Customer success lead, Marketing for joint campaigns, No dedicated resources yet
• Do you have any active NDAs, data security or compliance constraints that would limit integrations or customer introductions? Options: Yes—major constraints, Some constraints, No constraints, Unsure
• How stable is your executive sponsorship—if a sponsoring exec at a partner changed roles, how likely is the relationship to continue? Options: Very likely to continue, Somewhat likely, Unlikely, Would probably be orphaned
• Who on your side would be our escalation contact for stalled introductions or integration blockers? Options: CEO / Founder, Head of Partnerships, VP Sales, VP Engineering, Other
• Estimate how long it would take your team to onboard a named enterprise customer introduced by our teams (integration, POC, and legal close): Options: <30 days, 30–60 days, 60–90 days, >90 days

How Will You Know This Was Worth It?

• If you were to look back a year from now, what three outcomes would make you say the strategic investment was a clear success?
• Which of these measurable indicators would satisfy your lead VC that the partnership did not harm future rounds? Options: No restrictive governance clauses, Faster VC follow‑on interest, Independent market perception unchanged, Clear revenue attribution to partnership, Positive references from partner's customers
• How should we document and validate delivery—monthly dashboards, joint business reviews, signed case studies, or something else? Options: Monthly dashboard, Quarterly joint business review, Signed customer case studies, Ad hoc updates as needed, Other
• What acceptance criteria would your board require before recognizing the partnership as 'on track'?
• If early indicators are poor, what remediation steps would you expect from a corporate investor to fix course? Options: Reassign sponsor, Increase technical support, Pause commitments until fixed, Provide financial levers, Other

If We Were To Move Forward Tomorrow — What Would You Need?

• What is the minimum set of legal and governance terms that would allow you to sign a term sheet within your timeline?
• Which of these timelines best describes how fast your board could authorize and close with a quick, standard term sheet? Options: Within 1 week, 1–2 weeks, 2–4 weeks, More than 4 weeks
• Would you need introductions to references (our portfolio CEOs) before you sign, or can those be completed in parallel to closing? Options: Need before signing, Can be concurrent, Not necessary
• What would be your top three negotiation priorities for governance and commercial commitments?
• Finally, what single concern could derail a deal immediately—call it the 'showstopper'—and how can we preempt it?

A Quick Snapshot — Who You Are and What's at Stake

• Please introduce yourself: your role, company name, stage, and the round you're raising.
• Which revenue band best describes your business today (ARR or trailing 12 months)? Options: Pre‑revenue, Under $1M, $1M–$5M, $5M–$15M, $15M–$50M, $50M+
• Which customer segments or buyer personas are you focused on right now? Options: Platform/Infrastructure teams, Security teams, Data/Analytics teams, DevTools/Engineering orgs, Industry vertical buyers (finance/healthcare/etc.), SMB buyers, Other
• Describe your primary GTM motion today and any hybrid elements (direct sales, self‑serve, channel, marketplace). Options: Direct enterprise sales, Field sales + SDR/AEs, Self‑serve / product‑led growth, Channel/partner enabled, Marketplace driven, Hybrid
• Roughly how long have you been actively pursuing enterprise customers and what does your typical sales cycle look like today?
• Who on your leadership team will be the main drivers of a strategic investor relationship post‑close (names/roles)? Options: CEO, Head of Sales/Revenue, Head of Product, Head of Partnerships/BD, CTO/Head of Engineering, Other

The Board Room Whisper — What Are They Really Worried About?

• If your board could name one fear about adding a corporate investor that keeps them up at night, what would it be and why is it urgent now?
• Which of these board/lead VC concerns have surfaced in conversations so far? Options: Signals acquisition risk to market, Strategic governance slows future rounds, ROFR or exclusivity clauses, Forced board seat or special veto rights, Investment committee delays, Orphaning after initial enthusiasm, Other
• Who on the board or cap table is most skeptical, and how have they articulated their objections?
• How many portfolio CEOs has your lead VC asked about this corporate investor (or how many have you spoken to), and what did you hear back in one sentence? Options: None, 1, 2–3, 4–6, 7+
• What specific acceptance criteria (examples: committee speed, no exclusivity, reference checks) has the board demanded before they'd support taking strategic capital?
• And how do these board concerns feel emotionally—to you and the founder team—when you imagine scaling with a corporate partner? Options: Anxious, Cautiously optimistic, Frustrated, Relieved if mitigated, Other

Where Customers Actually Buy — Your GTM Truths

• What's the single biggest friction that turns a promising enterprise conversation into 'we'll revisit next quarter'?
• Which account types or verticals consistently close fastest for you, and why do you think that happens?
• Please break down your pipeline by approximate percentage: enterprise (> $50k ACV), mid‑market, SMB. Options: Enterprise >60%, Enterprise 30–60%, Enterprise <30%, Predominantly mid‑market, Predominantly SMB
• Which buying committee roles are most influential in closing deals for you (select all that apply)? Options: CIO/CTO, VP/Head of Engineering, Security Lead, Data/Analytics Lead, Procurement/Legal, Head of Product, Other
• How have integrations, partner endorsements, or co‑seller introductions materially changed deal outcomes in the past? Give a concrete example.
• Where in your current sales process do you lose momentum most often (e.g., POC stage, procurement/legal, executive alignment)? Options: POC/Proof of Value, Procurement/Legal, Security/compliance review, Executive sponsor alignment, Pricing/contract negotiation, Other

If We Took Corporate Money — How Would the World Perceive You?

• Imagine an announcement that a large strategic parent has invested—what's the first real way your customers, partners, or VCs would react?
• How concerned are you that a corporate investment will be interpreted as 'pre‑acquisition' by prospects or later‑stage VCs? Options: Very concerned, Somewhat concerned, Neutral, Not concerned
• Which existing partner or investor relationships would be most at risk from perceived acquisition signaling, and why?
• What public or private messaging tactics have you considered to preserve independence while accepting strategic capital (select all that apply)? Options: Explicit governance limits in public statement, Commitment to independence in press release, No product exclusivity pledge, Highlighting standard VC terms, No external messaging change, Other
• Have you managed market perception trade‑offs in previous rounds? What worked and what backfired?

What 'Real' Commercial Value Looks Like — The Metrics That Matter

• If we promise your pipeline will accelerate 6–12 months, what's the single measurable change you would require to believe that claim?
• Which KPIs would you prioritize to demonstrate success from a strategic investor (choose up to three)? Options: Deal velocity (time from SQL to close), Number of qualified opportunities created, Average ACV increase, Conversion rate from intro to opportunity, Number of joint POCs/pilots, Referenceable customers gained, Other
• What introduction cadence from a strategic investor would meaningfully move the needle in the first 90 days? Options: Weekly targeted intros, Bi‑weekly intros and enablement, Monthly scoped intros, Ad hoc as opportunities arise, None—intros are low value
• How many qualified, influenceable introductions per quarter would materially change your forecast (give a number or range)?
• What internal resources must the strategic investor commit (SE time, integration engineering, co‑sell training) to hit those KPIs? Options: Dedicated SE time, Integration engineering support, Joint account planning, Marketing/co‑demand gen, Executive sponsorship, Other
• Which mechanism would you prefer for validating outcomes—shared dashboard, weekly working sync, quarterly business review, or a combination? Options: Shared dashboard (live metrics), Weekly operational sync, Monthly reviews, Quarterly business reviews, Combination of above

Terms, Red Lines, and Governance — What Would Make You Say No?

• Which single contractual provision would make you walk away even if the commercial upside seemed strong?
• From the list below, select the governance provisions that you consider absolute deal breakers. Options: Exclusivity clauses, Right of first refusal (ROFR) on future rounds, Forced/appointed board seat, Veto rights over strategic pivots, Long‑term product exclusivity, Other
• What reasonable, narrowly scoped governance limits would you accept to reassure your lead VC while preserving strategic value?
• What standard financial VC terms do you expect from a corporate investor (e.g., liquidation preference, pro rata, anti‑dilution)?
• Would you accept operational annexes (time‑bound SLAs for intros, integration deliverables) instead of long strategic covenants to speed the legal process? Options: Yes, Maybe, No
• Which legal or governance approvals are required on your side before you can sign (select all that apply)? Options: CEO only, CEO + lead investor, Full board sign‑off, Comp committee, Legal counsel sign‑off, Other

Speed vs. Certainty — Which Wins for Your Round?

• If forced to choose: would your board prefer a faster close with narrow, measurable commitments or a longer process promising broader strategic guarantees? Options: Faster close with narrow commitments, Longer process with broader guarantees, Undecided / depends on details
• What is the absolute latest date you must have this round closed to avoid hurting hiring, product milestones, or go‑to‑market plans? Options: Within 2 weeks, Within 1 month, Within 2 months, Within 3 months, No fixed date
• If we can close within three weeks by committing to simple, auditable SLAs, would that materially outweigh seeking broader but slower commitments? Options: Yes, Maybe, No
• What internal actions would you prioritize to support a three‑week close (e.g., board pre‑reads, reference list, legal playbook)?
• How many distinct internal and external stakeholders must we satisfy to close (select the closest)? Options: 1–2 (CEO ± lead VC), 3–4 (CEO + lead VC + select board members), 5+ (full board consensus + major investor approvals)
• If introductions promised at close were delayed for 3–6 months, how would that impact your ability to meet the outcomes tied to the investment?

How We'll Measure Success Together — Signals, Cadence, and Escape Hatches

• At 90 days post‑onboarding, if you don't see measurable pipeline lift, what would you need from the investor to keep the relationship intact?
• Select the top three success signals you would present to your board to justify taking corporate capital. Options: % increase in qualified pipeline, Time reduction from lead to opportunity, First enterprise customer closed via co‑sell, Integrated product in customer pilot, Referenceable enterprise customer, Incremental ACV per closed deal
• Which acceptance criteria must be satisfied to call onboarding 'complete' (provide concrete thresholds or milestones)?
• How often would you want operational check‑ins and executive reviews during the first six months? Options: Weekly operational syncs, Bi‑weekly working meetings, Monthly exec reviews, Quarterly business reviews, Other
• Are you willing to share pipeline data for joint tracking? If so, what level of detail is acceptable? Options: De‑identified aggregate metrics, Named accounts with non‑sensitive details, Full named pipeline access, No pipeline sharing
• What 'escape' or remediation clauses would you want if the commercial relationship stalls (examples: right to unwind after X months, increased support commitments, termination of certain clauses)?
• Would you agree to speak with three of our portfolio CEOs as part of your diligence? If yes, what referral format do you prefer? Options: Live intro call, Recorded testimonial, Written reference, No, not at this stage